Form 4: Lemaitre Vascular Director Joseph P. Pellegrino Jr. Reports Accrual of Dividend Equivalent Rights
Insider Transaction Report
Lemaitre Vascular Inc. Director Joseph P. Pellegrino Jr. has reported the acquisition of various dividend equivalent rights tied to previously granted restricted stock and performance share unit awards.
Summary
- Joseph P. Pellegrino Jr., a Director at Lemaitre Vascular Inc. (LMAT), reported the acquisition of multiple tranches of Dividend Equivalent Rights (DERs) on May 29, 2025.
- These DERs accrued on existing Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards previously granted to Mr. Pellegrino Jr. on various dates between December 2, 2020, and December 6, 2024.
- The acquired DERs include 0.8606, 1.6382, 3.3357, 3.3357, 4.2768, 5.1249, and 4.1273 units, totaling approximately 22.7992 dividend equivalent rights.
- Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with its underlying RSU or PSU award.
- Following these transactions, Mr. Pellegrino Jr. beneficially owns various amounts of DERs, including 16.4748, 24.0078, 32.0117, 31.3287, 22.3098, 22.9751, and 8.1049 units across different award types.
Sentiment
Score: 6
Explanation: The document reports routine accruals of dividend equivalent rights as part of a director's compensation, which is a neutral to slightly positive event as it confirms the ongoing value and vesting of existing equity awards.
Positives
- The accrual of Dividend Equivalent Rights indicates that the underlying equity awards (Restricted Stock Units and Performance Share Units) granted to the director remain active and are accruing value, aligning the director's interests with shareholders.
- This filing represents a routine compensation event for a director, reflecting the ongoing vesting and dividend accrual of previously granted equity incentives.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions related to compensation and does not provide broader insights into industry trends or competitive dynamics within the vascular medical device sector.
Related Party Transactions
- The reported transactions involve the accrual of Dividend Equivalent Rights to Joseph P. Pellegrino Jr., a Director of Lemaitre Vascular Inc., which constitutes a compensation-related dealing between the company and a related party.
Stakeholder Impact
- Shareholders: Minimal direct impact, as this is a routine compensation accrual. It confirms the director's continued equity participation and alignment with shareholder interests through existing incentive plans.
Key Dates
| Date | Description |
|---|---|
| 12/02/2020 | Grant date of a Restricted Stock Unit (RSU) award on which dividend equivalent rights accrued. |
| 12/11/2021 | Grant date of a Restricted Stock Unit (RSU) award on which dividend equivalent rights accrued. |
| 12/12/2022 | Grant date of a Restricted Stock Unit (RSU) award and a Performance Share Unit (PSU) award on which dividend equivalent rights accrued. |
| 12/08/2023 | Grant date of a Restricted Stock Unit (RSU) award and a Performance Share Unit (PSU) award on which dividend equivalent rights accrued. |
| 12/06/2024 | Grant date of a Restricted Stock Unit (RSU) award on which dividend equivalent rights accrued. |
| 05/29/2025 | Transaction date for the acquisition of all reported Dividend Equivalent Rights. |
| 06/02/2025 | Signature date of the reporting person for the Form 4 filing. |
Recommendation
holdKeywords
Lemaitre Vascular, LMAT, SEC Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Joseph P Pellegrino Jr, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.